Aducanumab clinical trials
Also written BIIB037 and Aduhelm.
How each study uses aducanumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 7 Jun 2021 · ADUHELM · BLA 761178 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2015 | 3 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 1
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses aducanumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) TherapyActive, not recruitingEarly Phase 1Ali RezaiNCT05469009Written as AducanumabHow we know
- A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's DiseaseTerminatedPhase 3BiogenNCT05310071Written as AducanumabHow we know
- A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205TerminatedPhase 3BiogenNCT04241068Written as AducanumabHow we know
- A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy VolunteersCompletedPhase 1BiogenNCT05216887Written as AducanumabHow we know
- A Study to Assess Absolute Bioavailability of Aducanumab in Healthy VolunteersCompletedPhase 1BiogenNCT04924140Written as AducanumabHow we know
- A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging AbnormalitiesTerminatedPhase 2BiogenNCT03639987Written as AducanumabHow we know
- 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's DiseaseTerminatedPhase 3BiogenNCT02477800Written as Aducanumab (BIIB037)How we know
- 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's DiseaseTerminatedPhase 3BiogenNCT02484547Written as Aducanumab (BIIB037)How we know
- Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's DiseaseCompletedPhase 1BiogenNCT02434718Written as AducanumabHow we know
- Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's DiseaseTerminatedPhase 1BiogenNCT01677572Written as Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)How we know
- Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy ParticipantsCompletedPhase 1BiogenNCT02782975Written as aducanumabHow we know
- Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's DiseaseCompletedPhase 1BiogenNCT01397539Written as BIIB037How we know
As the comparator · 1 — what is tested is compared with aducanumab
Codes
What other systems call aducanumab · ClinicalTrials.gg INT000291
- MeSH (NLM) C000600266aducanumabOne source NLM
- UNII (FDA) 105J35OE21ADUCANUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2557217Confirmed FDA, Wikidata
- Wikidata Q15708278aducanumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166444AducanumabOne source FDA
- DrugBank DB12274One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000600266 | aducanumab | One source NLM |
| UNII (FDA) | 105J35OE21 | ADUCANUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2557217 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15708278 | aducanumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166444 | Aducanumab | One source FDA |
| DrugBank | DB12274 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.